MD3499F1 - Method of differentiated treatment of endometrial cancer - Google Patents
Method of differentiated treatment of endometrial cancerInfo
- Publication number
- MD3499F1 MD3499F1 MDA20070281A MD20070281A MD3499F1 MD 3499 F1 MD3499 F1 MD 3499F1 MD A20070281 A MDA20070281 A MD A20070281A MD 20070281 A MD20070281 A MD 20070281A MD 3499 F1 MD3499 F1 MD 3499F1
- Authority
- MD
- Moldova
- Prior art keywords
- series
- level
- tryptophanhydroxylase
- differentiation
- stage
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Inventia se refera la medicina, in special la oncologia ginecologica. Esenta metodei de tratament diferentiat al cancerului endometrial consta in aceea ca se stabileste stadiul bolii, gradul de diferentiere, nivelul de invazie miometriala, se determina nivelul triptofanhidroxilazei-1. In cazul in care nivelul triptofanhidroxilazei-1 este mai inalt de 13,8 unitati conventionale, iar la paciente se stabileste stadiul bolii IA, IB, gradul de diferentiere 1, 2 si 3, invazie miometriala mai putin de 50% sau stadiul IC, gradul de diferentiere 1 si2 si invazie miometriala mai mult de 50%, se efectueaza histerectomia totala cu salpingooforeńtomiebilaterala. In cazul cand nivelul triptofanhidroxilazei-1 variaza de la 3,6 pana la 13,8 unitati conventionale, dupa histerectomie, suplimentar, se indica doua serii de chimioterapie cu Cisplatina - 100 mg/m2 in perfuzie timp de 4 ore, o data la serie si concomitent se indica hormonoterapie cu Depo-provera - 500 mg, intramuscular, o data pe saptamana si antiestrogenoterapie cu Tamoxifen - 20 mg/zi, seria constituind 3 luni cu interval de 3 saptamani intre serii.The invention refers to medicine, especially gynecological oncology. The essence of the method of differentiated treatment of endometrial cancer is that the stage of the disease is determined, the degree of differentiation, the level of myometrial invasion, the level of tryptophanhydroxylase-1 is determined. If the level of tryptophanhydroxylase-1 is higher than 13.8 conventional units, and in patients the stage of the disease IA, IB, the degree of differentiation 1, 2 and 3, the myometrial invasion less than 50% or the stage IC, the degree is established of differentiation 1 and 2 and myometrial invasion more than 50%, total hysterectomy with salpingoophoreńtomiebilateral is performed. If the tryptophanhydroxylase-1 level ranges from 3.6 to 13.8 conventional units, after hysterectomy, additionally, two series of chemotherapy with Cisplatin - 100 mg / m2 in infusion for 4 hours, once in series, are indicated. and at the same time, hormone therapy with Depo-provera - 500 mg, intramuscularly, once a week and anti-estrogen therapy with Tamoxifen - 20 mg / day is indicated, the series constituting 3 months with a 3-week interval between series.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20070281A MD3499G2 (en) | 2007-10-12 | 2007-10-12 | Method of differentiated treatment of endometrial cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20070281A MD3499G2 (en) | 2007-10-12 | 2007-10-12 | Method of differentiated treatment of endometrial cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD3499F1 true MD3499F1 (en) | 2008-02-29 |
| MD3499G2 MD3499G2 (en) | 2008-09-30 |
Family
ID=39156456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20070281A MD3499G2 (en) | 2007-10-12 | 2007-10-12 | Method of differentiated treatment of endometrial cancer |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD3499G2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2547569C1 (en) * | 2014-02-03 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method of treating patients suffering locally advanced cervical cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD186C2 (en) * | 1994-03-01 | 1995-09-30 | Etco Ludmila | Method of endometritis treatment after cesarean section |
| MD2377G2 (en) * | 2003-09-18 | 2004-08-31 | Институтул Де Черчетэрь Штиинцифиче Ын Домениул Окротирий Сэнэтэуий Мамей Ши Копилулуй Ал Министерулуй Сэнэтэций | Method of treatment of puerperal endometritis |
| MD3222G2 (en) * | 2006-03-22 | 2007-08-31 | Общественное Медико-Санитарное Учреждение Онкологический Институт | Method of endometrial cancer diagnosis |
-
2007
- 2007-10-12 MD MDA20070281A patent/MD3499G2/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2547569C1 (en) * | 2014-02-03 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method of treating patients suffering locally advanced cervical cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| MD3499G2 (en) | 2008-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michmerhuizen et al. | PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation | |
| Jafari et al. | HSP90 and co-chaperones: impact on tumor progression and prospects for molecular-targeted cancer therapy | |
| EP3483288A3 (en) | Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support | |
| Lee et al. | Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer | |
| Giancola et al. | Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? | |
| UA106756C2 (en) | genetic markers associated with response to interferon alpha | |
| MA39094A1 (en) | Combination therapy comprising an inhibitor of mdm2 and one or more additional pharmaceutically active principles for the treatment of cancers | |
| MA33469B1 (en) | POLYTHERAPY BASED ON AFUCOSYLATED ANTI-CD20 ANTIBODY AND BENDAMUSTIN | |
| EP2559434A3 (en) | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist | |
| MX2014002967A (en) | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells. | |
| Abbott | Dasatinib: from treatment of imatinib-resistant or-intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia | |
| RU2015145997A (en) | ANTITUMORIC MEDICINE, INCLUDING LOW-DOSED IRINOTECANE HYDROCHLORIDE HYDRATE | |
| MX2021013711A (en) | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3 -yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients. | |
| MD3499F1 (en) | Method of differentiated treatment of endometrial cancer | |
| EA201071422A1 (en) | METHODS OF TREATING DISEASES ASSOCIATED WITH MEIOTIC KINESIN | |
| FR2910324B1 (en) | NEW MEDICINE FOR THE TREATMENT OF GASTRIC CANCER | |
| MD3616F1 (en) | Method of differentiated treatment of endometrial carcinoma | |
| Iacobucci | NICE recommends routine NHS funding for new breast cancer drugs | |
| RU2010122941A (en) | METHOD FOR PREVENTING SEVERE GESTOSIS | |
| RU2009125384A (en) | METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PREGNANT WOMEN WITH IRON DEFICIENCY ANEMIA | |
| Gill et al. | Controlling the cost of breast cancer. | |
| JP2018502087A5 (en) | ||
| Fedyanin et al. | Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study | |
| MD3222F1 (en) | Method of endometrial cancer diagnosis | |
| Hryciuk et al. | Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |